PriceTargets.com logo

Celadon Pharmaceuticals - CEL Stock Price Target and Predictions

  • Consensus Rating: N/A
  • Consensus Price Target: GBX 0
  • Forecasted Upside: -100.00%
  • Number of Analysts: 0
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
GBX 4.11 As of 04/4/2025 01:38 PM ET
▼ -1.89 (-31.50%)

This chart shows the closing price for CEL by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
FebMarApr4.11Closing price on 04/05/25:
Get New Celadon Pharmaceuticals Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for CEL and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for CEL

Analyst Price Target is GBX 0
▼ -100.00% Downside Potential
This price target is based on 0 analysts offering 12 month price targets for Celadon Pharmaceuticals in the last 3 months. The average price target is GBX 0, with a high forecast of GBX 0 and a low forecast of £100,000. The average price target represents a -100.00% upside from the last price of GBX 4.11.

This chart shows the closing price for CEL for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart
4/247/249/2412/244/254/262.103567100132Closing price on 04/05/25: 4.11High0.0000Average0.0000Low10.00M




Current Consensus is N/A

The current consensus among 0 investment analysts is to n/a stock in Celadon Pharmaceuticals. This rating has held steady since September 2024, when it changed from a Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
10/13/2023
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
1/11/2024
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
4/10/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
7/9/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
10/7/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
1/5/2025
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/6/2025
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
4/5/2025

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
9/29/2023Canaccord Genuity GroupBoost TargetSpeculative BuyGBX 210 ➝ GBX 235
6/5/2023Canaccord Genuity GroupReiterated RatingSpeculative BuyGBX 210
4/20/2023Canaccord Genuity GroupReiterated RatingSpeculative BuyGBX 210
5/30/2022Canaccord Genuity GroupInitiated CoverageSpeculative BuyGBX 210
(Data available from 4/5/2020 forward)

News Sentiment Rating

0.00 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 1 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
9/7/2024
  • 0 very positive mentions
  • 5 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
10/7/2024
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/6/2024
  • 1 very positive mentions
  • 1 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
12/6/2024
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
1/5/2025
  • 0 very positive mentions
  • 1 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
2/4/2025
  • 1 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
3/6/2025
  • 0 very positive mentions
  • 2 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
4/5/2025

Current Sentiment

  • 0 very positive mentions
  • 2 positive mentions
  • 1 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

Positive

Very Positive

  • No very positive mentions tracked during this time.
Celadon Pharmaceuticals logo
Celadon Pharmaceuticals Plc is a UK-based pharmaceutical company focused on the development, production and sale of breakthrough cannabis-based medicines. Its primary focus is on improving quality of life for chronic pain sufferers, as well as exploring the potential of cannabis-based medicines for other conditions such as autism. Its 100,000 sq. ft UK facility is EU-GMP approved and comprises indoor hydroponic cultivation, proprietary GMP extraction and an analytical and R&D laboratory. Celadon's Home Office licence allows for the commercial supply of its pharmaceutical-grade cannabis product. The Group owns an approved clinical trial using cannabis-based medicinal products to treat chronic pain in the UK. Celadon also has a minority interest in early-stage biopharma Kingdom Therapeutics, which is developing a licensed cannabinoid medicine to treat children with Autism Spectrum Disorder. For further information please visit our website www.celadonpharma.com
Read More

Today's Range

Now: GBX 4.11
Low: 3.16
High: 6.10

50 Day Range

MA: GBX 15.40
Low: 3
High: 22

52 Week Range

Now: GBX 4.11
Low: 2.21
High: 122.50

Volume

626,330 shs

Average Volume

288,347 shs

Market Capitalization

£2.52 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of Celadon Pharmaceuticals?

The following Wall Street sell-side analysts have issued stock ratings on Celadon Pharmaceuticals in the last twelve months:
View the latest analyst ratings for CEL.

What is the current price target for Celadon Pharmaceuticals?

0 Wall Street analysts have set twelve-month price targets for Celadon Pharmaceuticals in the last year. has the lowest price target set, forecasting a price of £100,000 for Celadon Pharmaceuticals in the next year.
View the latest price targets for CEL.

What is the current consensus analyst rating for Celadon Pharmaceuticals?

Celadon Pharmaceuticals currently has from Wall Street analysts. The stock has a consensus analyst rating of "N/A."
View the latest ratings for CEL.

What other companies compete with Celadon Pharmaceuticals?

Other companies that are similar to Celadon Pharmaceuticals include Cambridge Nutritional Sciences, Fox Marble, Oxford Technology 3 Venture Capital Trust, Beacon Energy and Curzon Energy. Learn More about companies similar to Celadon Pharmaceuticals.

How do I contact Celadon Pharmaceuticals' investor relations team?

Celadon Pharmaceuticals' physical mailing address is 32-33 Cowcross Street, London EC1M 6DF, United Kingdom. The company's listed phone number is 44 20 3150 0252. The official website for Celadon Pharmaceuticals is www.celadonpharma.co.uk. Learn More about contacing Celadon Pharmaceuticals investor relations.